Foundayo Launches, FY26 Guide Raised by $2B, Retatrutide Type-2 Diabetes Reads Through — Maintaining Outperform, FV $1,000–1,200

Rating Action: Walking the Arc Q2 25 → Today

Our coverage walk, period-by-period:

• Q2 2025 (Initiating at Hold, constructive bias). We initiated coverage with the view that the GLP-1 franchise was uncontested as a growth story, but the stock’s premium multiple and the structural drag of negotiated price reductions (MFN, China NRDL, direct-to-patient) made the risk/reward symmetric on the way up. We wanted to see oral-GLP-1 execution in real numbers before paying for what could have been an overpriced launch curve.
• Q3 2025 (Upgrading to Outperform). Six positive Phase III orforglipron readouts cleared the regulatory gating concern; international Mounjaro ramp confirmed OUS volumes could carry growth as US obesity matured; share gains in US incretins continued for a fifth consecutive quarter; and the FY25 guide raise signaled management still saw underlying-demand upside. We moved to Outperform on the durable-leadership case being decisively confirmed.
• Q4 2025 (Maintaining Outperform). The FY26 guide reset validated the upgrade: a low- to mid-teens price drag was disclosed and absorbed into a +25% revenue, +40% EPS framework. Manufacturing capacity was demonstrably caught up (2025 incretin doses 1.8x 2024); orforglipron US obesity submission and ATTAIN-MAINTAIN switching data set up the Q2 2026 launch. We held Outperform with the orforglipron approval as the proximate catalyst.
• Q1 2026 (Today — Maintaining Outperform). The three open items at the upgrade resolved in a single print: pricing held within the disclosed corridor; Foundayo launched with broad commercial access and no obvious operational misses; the BD slate read as additive rather than diluting capital allocation. The FY26 guide raise of $2B is volume-sourced — the cleanest version of the bull case. Pipeline optionality across retatrutide, eloralintide, Foundayo’s six additional Phase III programs in non-obesity indications, and the Orna/Sytesa/Colonia/Ajax acquisitions has expanded, not contracted, on a real-dollar basis. The franchise that had been priced for execution risk has now executed; we maintain Outperform with FV refined to $1,000–1,200.

Results vs. Consensus

Lilly does not pre-disclose Street consensus inside its release; the comparison below uses the consensus estimates we tracked into the print.

The non-GAAP EPS line is flattered roughly $1.20 by a much-lower IPR&D charge year-over-year. Stripping that, the underlying operating beat is still in the $0.80–0.90 range (~10%) — clean and broad-based.

Segment / Therapeutic-Area Performance

Cardiometabolic (Mounjaro + Zepbound/Suven): The Engine

Combined Mounjaro and Zepbound/Suven worldwide revenue was $12.8B, a $6.7B incremental contribution versus Q1 2025. The dynamics by region:

• U.S.: revenue +43%, with U.S. price down 7% (or down 10% excluding a one-time rebate-and-discount estimate adjustment that primarily benefited Suven and Mounjaro). Volume more than absorbed the price pressure. The total U.S. incretin obesity market grew prescriptions >80% YoY; Suven prescriptions grew faster than the market; Suven’s self-pay channel remained robust at ~45% of total prescriptions and 55% of new prescriptions. Loss of Medicaid access in certain states cost the prescription line "high single digits" of growth.
• Europe: revenue +37% in constant currency, sustained Mounjaro volume growth.
• Japan: revenue +42% in constant currency, Mounjaro for T2D.
• China: revenue accelerated with Mounjaro’s inclusion on the National Reimbursement Drug List for T2D — price concession but volume "far outstripping" the give.
• Rest of World: revenue more than doubled in constant currency — rapid Mounjaro share gains in Latin America and Asia.

U.S. Type 2 diabetes incretin-analog total prescriptions grew 11%; Mounjaro gained another 3 percentage points of market share vs. exit-2025 levels.

Immunology

Ebglyss U.S. new patient starts +90% YoY in atopic dermatitis. The Phase IIIb open-label extension showed durable disease control out to 4 years on once-monthly dosing, with 75% of patients achieving near-complete skin clearance and 80% maintaining results without topical corticosteroids. Phase III Adorable-Lyne in pediatric atopic dermatitis (ages 6 months and older) hit endpoints with 63% of children achieving EASI-75 and 44% achieving IGA 0/1. Submission for the once-every-8-weeks maintenance regimen is under FDA review with action expected later this year.

Together-PSO (Phase IIIb) showed 27% of patients on Taltz (ixekizumab) plus tirzepatide achieving co-primary endpoint of total skin clearance plus ≥10% weight loss in psoriasis with obesity, versus <6% on Taltz alone — the second positive trial demonstrating incretin-immunology combination value.

Oncology

Pirtobrutinib (Jaypirca) worldwide sales +79% YoY. The major news was the BRUIN-CLL-322 Phase III readout: pirtobrutinib added to a fixed-duration venetoclax/rituximab regimen significantly extended PFS versus the venetoclax-control arm — the first medicine ever to beat a venetoclax-containing control in a Phase III CLL trial. Combined with prior wins in BRUIN-CLL-313 and BRUIN-CLL-14, pirtobrutinib has now succeeded across 4 Phase III studies in CLL covering monotherapy, combination, post-BTK, and now venetoclax-based settings. Inluriyo’s first full quarter post-launch saw >35% share of new patient starts in metastatic breast cancer.

Neuroscience

Kisunla remains the U.S. leader in amyloid-targeting Alzheimer’s therapies; the company expects European launches to begin contributing through 2026. A Phase III program in major depressive disorder was initiated for brenepatide (a GLP-1/GIP dual agonist with a CNS investigational case), plus Phase II programs in opioid use disorder and schizophrenia and two new pain assets entered Phase II. The Cintessa Pharmaceuticals acquisition adds an orexin-receptor-2 agonist platform led by emanarexton with best-in-class profile for excessive daytime sleepiness.

Key Topics & Management Quotes

Foundayo (orforglipron) launch trajectory

Lilly U.S. President Ilya Yuffa framed the early launch metrics:

"We now have over 8,000 prescribers of Foundayo, 1/3 of which who have not previously written an oral GLP-1. ... we now have just over 20,000 patients treated to date. ... 80% of those found prescriptions are new to class. So this is expansive in bringing new people into being treated for overweight or obesity." — Ilya Yuffa, President, Lilly USA & Global Customer Capabilities

The launch sequencing matters: broad pharmacy availability April 9, in-person HCP promotion began April 17, full DTC TV begins Q3 (deliberately staged to give prescribers time to absorb the clinical profile before consumer demand hits the market). Two of the three largest U.S. PBMs activated commercial access by mid-May; Medicare bridge starts no later than July 1, 2026.

Pricing-volume framework

CEO David Ricks on the price-volume relationship in the obesity category:

"Pretty much every time we reduce pricing, we see a pretty large expansion. ... like Lilly’s eons really had quite a strong quarter in Q1 and with at slightly lower prices. And then in China, we negotiated for diabetes access at a meaningful price reduction, but you can see the volume far outstripping the price concession." — David Ricks, Chair & CEO

The structural framing: the obesity-medicine market is more akin to a consumer-discretionary elasticity curve than a traditional pharma price-protected one — out-of-pocket exposure is high (75% of ex-U.S. Mounjaro is self-pay), and the unit economics rest on largely sunk fixed-cost manufacturing investment, so there is "latitude" at the margin to invest in new medicines without compressing the operating profile.

Retatrutide T2D readout

CSO Daniel Skovronsky on the TRANSCEND-T2D-1 results:

"We saw that participants lost an average of 11.1 to 16.6 kilograms were 25 to 37 pounds. While cross-trial comparisons of limitations, these data suggest renotrutide can deliver [glycemic] control in line with the most widely prescribed anchored therapy for type 2 diabetes, tirzepatide, while delivering additional weight loss." — Dr. Daniel Skovronsky, Chief Scientific & Product Officer

The thesis read-through: retatrutide offers a meaningful weight-loss advance over tirzepatide while delivering comparable A1c efficacy, expanding the cardiometabolic franchise into a higher-efficacy tier without cannibalizing it.

Pirtobrutinib in CLL

Skovronsky on the BRUIN-CLL-322 result:

"[Pirtobrutinib] significantly extended progression-free survival compared to the fixed duration regimen and was the first medicine to utilize and outperform a venetoclax control containing control arm in a Phase III in the history of CLL drug development." — Dr. Daniel Skovronsky

Medicare bridge mechanics

Ricks on the bridge-program extension and the path to permanent Part D coverage:

"I would expect the government to lean hard into getting Part D plan participation in ’28 and normalizing obesity care as a standard preventative treatment and something that should be used to treat comorbidities of obesity within the senior population. ... I think that normalization is overdue in the commercial market." — David Ricks

Margin framework

CFO Lucas Montarce on the margin trajectory:

"Gross margin as a percentage of revenue was 82.6% in Q1, a decrease of approximately 1 percentage point versus the same quarter last year. The change was driven primarily by lower realized prices." — Lucas Montarce, CFO

The performance-margin guide widening to 47–48.5% (vs. consensus closer to 46) suggests Lilly is comfortable that the price-mix headwind is offset by scale and product-mix shift toward higher-margin cardiometabolic SKUs.

Guidance: FY 2026

Notable: management did not revise the price-headwind framework. The full $2B raise is volume-sourced — the cleanest version of the bull case. Foundayo’s contribution to the raise was characterized as conservative; underlying Mounjaro/Suven strength carried the bulk.

Analyst Q&A: Themes & Paraphrases

The Q&A focused on six themes; each is paraphrased and attributed by analyst & firm for context. None of the questions are quoted verbatim.

• Pricing & volume elasticity in obesity (Jeff Meacham, Citi). The analyst pressed on whether Lilly’s sunk capacity investments leave room to take further price down without compressing operating margins. Ricks framed obesity as structurally different from traditional pharma pricing — expansionary volume responses to price reductions, with most unit-economic risk borne by amortized R&D and capex rather than gross margin. Latitude remains; investment cadence is the swing factor.
• International Mounjaro and the generic-semaglutide threat (Chris Schott, JPMorgan). Patrik Jonsson, President of Lilly International, characterized early India data as stimulating total market growth without material Mounjaro share erosion — Mounjaro prescriptions ~10% higher in recent weeks vs. pre-generic-launch. Mounjaro market share is >53% on average internationally, with several countries already at U.S. levels of share; future growth is patient-activation-led rather than share-take-led.
• Market segmentation across the next-gen obesity portfolio (Seamus Fernandez, Guggenheim). Ken Custer, President of Lilly CardioMetabolic Health, framed the market as a multi-modality landscape: GLP-1 single agonist, dual agonist, oral, and (forthcoming) eloralintide as a non-GLP-1 amylin option. Retatrutide positioned for higher-efficacy weight loss segments; eloralintide as either a non-GLP-1 alternative or as add-on to existing incretin therapies. Manufacturing platforms are common across the portfolio — capacity is fungible across whichever wins.
• Medicare access activation timeline (Alex Hammond, Wolfe). Yuffa framed Part D access as a 2027 build (gradual through 2026, full ramp in 2027), gated on physician/pharmacy/consumer education. The $50/month co-pay was characterized as additive to already-strong persistency observed in Zepbound and Mounjaro relative to chronic-disease norms.
• Foundayo launch trajectory and guidance contribution (Asad Haider, Goldman Sachs). Yuffa walked through the three launch levers (HCP familiarity, payer access, consumer awareness); CFO Montarce framed Foundayo’s contribution to the FY26 guide raise as conservative, with Mounjaro/Suven underlying strength doing the heavy lifting.
• Zepbound U.S. unit-economics math (Umer Raffat, Evercore). The analyst questioned whether IMS prescription data fully captures online channels given Zepbound’s ~$580/Rx implied U.S. realized price versus a ~$450 cash-pay benchmark. Montarce confirmed the math — Lilly Direct prices are stable since the December reduction, and the residual gap is the commercial-channel mix, with Ricks adding that medical-exception and OSA-indicated usage at undiscounted prices accounts for additional dollars.
• Employer Connect economics and adoption curve (Mohit Bansal, Wells Fargo). Yuffa described the platform as a transparent-pricing path for employers to opt into obesity coverage, with most adoption flowing through 2027 plan-year decisions given the 2026 selling cycle has largely closed. Ricks framed the broader question as a multi-year normalization curve toward the diabetes-and-hypertension chronic-coverage paradigm.

What They’re NOT Saying

• No specific Foundayo revenue line. Lilly disclosed prescriber count, patient count, and PBM access timing — but not a dollar revenue number for Foundayo’s first three weeks. The omission is consistent with management’s "early days, follow the indicators" framing, but it leaves the most consequential launch math to be inferred from prescription panels.
• No revised long-term operating-margin algorithm. The performance-margin floor moved up (47% from ~46%), but Lilly did not refresh the FY27 or FY28 framework. With Foundayo ramping and retatrutide/eloralintide approaching pivotal readouts, the absence of an updated long-term margin path leaves room for either upside or for management to stay defensive against pricing surprises.
• No formal capacity disclosure for Foundayo. Ricks alluded to "extreme amounts of inventory pre-prepared" via the Courtney Breen question, and Patrik Jonsson noted 40+ ex-U.S. registration filings underway, but Lilly did not quantify Foundayo’s production envelope. The international rollout is the bigger story than U.S. supply — and the supply line is the gating function for that rollout.
• No commentary on Foundayo’s pricing strategy. The question of whether Foundayo prices at, above, or below Zepbound’s self-pay channel was not addressed directly. Cash-pay positioning will materially shape the launch curve; the omission is conspicuous.
• No update on the long-term >$20 EPS framework that has been referenced by management in prior cycles. The FY26 guide raise implies the trajectory, but there is no explicit re-affirmation of any multi-year framework.
• Limited tariff or geopolitical commentary. Given the MFN negotiation framing and the China NRDL concession, the path through 2H 2026 of further negotiated price reductions is a known unknown that received only glancing mention.

Market Reaction

Lilly reported Q1 2026 before the open on April 30, 2026. The pre-market reaction was constructive on the headline numbers and the guide raise, with the stock building on its YTD outperformance versus the large-cap pharmaceuticals peer group. The clean print — volume-led top-line beat, EPS roughly $1 above consensus, $2B raise to both ends of the FY guide, and the Foundayo launch metrics — left limited room for a rotational fade, in contrast to the AMD-style "beat-and-fade" patterns seen in semiconductor names entering prints with positioning extended.

The thesis-relevant market signal: the print did not need to defend the rating — it expanded the operating bull case while the pipeline did the heavy lifting on optionality. The post-print question shifted from "can the franchise absorb pricing pressure?" to "how aggressive does the long-term EPS path get if Foundayo, retatrutide, and eloralintide all execute?"

Street Perspective

Going into the print, the sell-side bull case rested on three pillars: Mounjaro/Zepbound volume momentum at international scale, Foundayo as a launch-quarter event, and the read-through from retatrutide’s Phase III T2D data. All three pillars cleared in this print:

• Bull-case validation: the volume-led top-line raise without rebasing the price-headwind framework is the cleanest version of the volume thesis. Mounjaro’s international ramp, Zepbound’s U.S. self-pay channel resilience, and pirtobrutinib’s expansion across CLL settings all add to the medium-term operating story.
• Bear-case retort: the Foundayo launch is “three weeks of data,” the gross margin trended down ~1 percentage point YoY, IPR&D charges flatter the EPS comparison, and the long-tail risk of further negotiated price concessions in 2H remains. Bears will note that 56% revenue growth and a 50% performance margin will be hard to anniversary, and that the FY27 framework is not yet refreshed.
• The middle-ground view: the print justifies the multiple but does not yet justify a meaningful multiple expansion. The bull-bear gap is now narrower than it has been in three quarters, and the catalyst path (retatrutide obesity Phase III readout later in Q2, Foundayo Q3 DTC ramp, Q4 prescriber-familiarity inflection) tilts asymmetric to the upside.

Model Implications

• FY26 revenue: we move our base case toward the upper half of the new $82–85B guide range, anchoring our point estimate at ~$84B (vs. our prior ~$81B). Q1’s +56% YoY against a price headwind suggests upside to the volume framework if Mounjaro’s international ramp continues and Foundayo absorbs greater commercial share than guidance contemplates.
• FY26 non-GAAP EPS: we set our point estimate at ~$36.25 (midpoint of the new range), with skew to the upper end if performance margin holds at 48–48.5% and IPR&D charges remain proportionate to revenue.
• FY27 outlook: our preliminary FY27 framework (subject to revision after the next R&D Day) targets $100–110B in revenue and ~$45–50 EPS, with the wedge driven by Foundayo at scale, ex-U.S. Foundayo launches, retatrutide approval and launch (assuming positive obesity Phase III), and continued expansion of immunology and oncology. The price-headwind framework is assumed to moderate as direct-to-patient pricing stabilizes.
• Gross margin: we model 82–83% for FY26 (range-bound, reflecting continued price compression offset by scale), with the long-term path bracketed at 81–83% subject to mix shift toward Foundayo (which carries different unit economics than injectables).
• Capital allocation: Lilly executed $1.5B in dividends and $2.4B in buyback in Q1; the BD slate (Orna, Sytesa/Cintessa, Carthronix/Colonia, Ajax) consumed an undisclosed but material amount. We continue to model BD as a steady ~$8–12B annual cadence; the IPR&D charge volatility will continue to flow through non-GAAP EPS quarterly.
• Fair value: we set a $1,000–1,200 fair-value range, anchored on ~22–26x our FY27 EPS estimate of ~$48 at midpoint. The range straddles current levels and reflects high conviction on the operating story balanced against multiple discipline; we do not chase the upper end of the range without further evidence on retatrutide’s obesity Phase III readout and Foundayo’s Q3/Q4 launch curve.

Thesis Scorecard